|
AU2012207022A1
|
|
Prodrugs containing novel bio-cleavable linkers
|
|
TW201300105A
|
|
A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck
|
|
TW201242597A
|
|
A synergistic pharmaceutical combination for the treatment of pancreatic cancer
|
|
CN103458906A
|
|
Process for preparation of a herbal extract
|
|
WO2012077031A1
|
|
Substituted imidazoquinoline derivatives
|
|
WO2012069972A1
|
|
A pharmaceutical combination for the treatment of breast cancer
|
|
CN103228633A
|
|
Heterocyclic compounds as DGAT1 inhibitors
|
|
WO2012020364A1
|
|
Di peptide derivative for the treatment of cancer
|
|
US2013017264A1
|
|
Alginate tube drug delivery system and method therefor
|
|
WO2011080718A1
|
|
Inhibitors of diacylglycerol acyl transferase
|
|
CN102666523A
|
|
Macrocyclic lactone derivatives for the treatment of cancer
|
|
KR20110057255A
|
|
Herbal composition and method for the treatment of viral infection
|
|
WO2010023609A1
|
|
Oxazole, oxadiazole and thiazole derivatives as diacylglycerol acyltranferase inhibitors
|
|
ZA200900900B
|
|
An enantioselective synthesis of pyrrolidine-substituted flavones
|
|
TW200908984A
|
|
Pyridyl derivatives, their preparation and use
|
|
TW200908958A
|
|
Tricyclic compounds for the treatment of inflammatory disorders
|
|
AU2008357875A1
|
|
Interferon Epsilon (IFNE1) as a marker for targeted cancer therapy
|
|
US2010034746A1
|
|
Animal model, system, and method for screening compounds for antithrombotic and/or thrombolytic activity
|
|
EP2121955A2
|
|
Method of use of epiregulin protein and nucleic acid encoding the same in inflammatory conditions
|
|
EP2077846A2
|
|
Benzoxazepine compounds, their preparation and use
|
